A carregar...
VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma
Immune recognition of tumor targets by specific cytotoxic lymphocytes is essential for the effective rejection of tumors. A phase I clinical trial of ipilimumab (an antibody that blocks CTLA-4 function) in combination with bevacizumab (an antibody that inhibits angiogenesis) in patients with metasta...
Na minha lista:
| Publicado no: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5050160/ https://ncbi.nlm.nih.gov/pubmed/27549123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0084 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|